AbGn-168H

BIOLOGICAL5 trials

Sponsors

Boehringer Ingelheim, AbGenomics B.V Taiwan Branch

Conditions

Acute Graft Versus Host DiseaseHealthyModerate to Severe Chronic Plaque PsoriasisPsoriatic Arthritis

Phase 1

Phase I Study of AbGn-168H in Healthy Male Volunteers

CompletedNCT01378364

Boehringer IngelheimHealthy

Start: 2011-06-30Updated: 2013-11-01

A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant

TerminatedNCT02436460

AbGenomics B.V Taiwan BranchAcute Graft Versus Host Disease

Start: 2015-05-31End: 2016-03-31Updated: 2017-03-30

Phase 2

Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients

CompletedNCT01855880

AbGenomics B.V Taiwan BranchModerate to Severe Chronic Plaque Psoriasis

Start: 2013-05-31End: 2014-03-31Updated: 2015-05-08

A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis

CompletedNCT02223039

AbGenomics B.V Taiwan BranchModerate to Severe Chronic Plaque Psoriasis

Start: 2014-05-31End: 2015-02-28Updated: 2016-04-14

A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis

CompletedNCT02267642

AbGenomics B.V Taiwan BranchPsoriatic Arthritis

Start: 2015-01-31End: 2016-01-31Updated: 2017-01-24